Orexigen(R) Therapeutics Announces Third Quarter 2008 Financi...(ent $- $- $- $-...)

License revenue 22 22 66 66 331

Total revenues 22 22 66 66 505

Operating expenses:

Research and

development 21,463 12,938 61,735 33,215 151,592

General and

administrative 3,638 2,694 11,049 7,402 33,220

Total operating

expenses 25,101 15,632 72,784 40,617 184,812

Loss from operations (25,079) (15,610) (72,718) (40,551) (184,307)

Other income (expense):

Interest income 662 1,322 2,800 2,800 8,364

Interest expense (370) (260) (1,196) (596) (2,106)

Total other income

(expense) 292 1,062 1,604 2,204 6,258

Net loss (24,787) (14,548) (71,114) (38,347) (178,049)

Accretion to redemption

value of redeemable

convertible preferred

stock - - - (11) (78)

Deemed dividend of

beneficial conversion

for Series C preferred

stock - - - - (13,860)

Net loss attributable

to common

stockholders $(24,787) $(14,548) $(71,114) $(38,358) $(191,987)

Net loss per share

attributable to

common stockholders

- basic and diluted $(0.72) $(0.54) $(2.12) $(2.40)

Shares used in

computing net loss

per share attributable

to common stockholders

- basic and diluted 34,355 26,905 33,539 16,003